文献速递膀胱癌与上尿路尿路上皮癌

吉西他滨/白蛋白结合型紫杉醇对比吉西他滨/卡铂治疗晚期尿路上皮癌

Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
PubMed 文献 · BJU Int · 2024-02-11

这项III期试验将顺铂不耐受的转移性尿路上皮癌初治患者随机分入GA组或GCb组,因入组缓慢在54例时提前终止。GA组与GCb组中位无进展生存期6.7 vs 5.9个月(P=0.248),中位总生存期12.1 vs 10.7个月(P=0.837),GA组3-4级血小板减少及剂量减少和延迟发生率显著更低。

要点

  • GA组与GCb组中位无进展生存期6.7 vs 5.9个月(P=0.248),无显著差异。
  • GA组3-4级血小板减少及剂量减少和延迟发生率显著低于GCb组。
  • GA组外周感觉神经病变发生率更高,但未发生3级神经病变。

核心结论

  • 虽未针对比较进行功效计算,一线GA显示出相似疗效和更好耐受性,可能被视为GCb的合理替代方案。

研究设计与样本

  • III期试验,纳入顺铂不耐受的转移性尿路上皮癌初治患者,随机分配至GA组或GCb组,因入组缓慢在54例时提前终止:GA组26例,GCb组28例。

主要发现

  • GA组与GCb组中位无进展生存期6.7 vs 5.9个月(P=0.248)。
  • GA组与GCb组中位总生存期12.1 vs 10.7个月(P=0.837)。
  • GA组与GCb组客观缓解率40% vs 46.4%(P=0.637),疾病控制率72% vs 68%(P=0.188)。
  • GA组3-4级血小板减少及剂量减少和延迟发生率显著低于GCb组。
  • GA组外周感觉神经病变发生率更高,但无3级神经病变发生;两组患者报告结局无差异。

关键数值与推荐

  • GA方案:白蛋白结合型紫杉醇125 mg/m2和吉西他滨1000 mg/m2,第1天和第8天给药,每21天一次。
  • GCb方案:卡铂游离血浆浓度-时间曲线下面积4.5,第1天;吉西他滨1000 mg/m2,第1天和第8天,每21天一次。

临床怎么用

  • 作者认为,一线GA显示出相似疗效和更好耐受性,可能被视为GCb的合理替代方案。

局限性

  • 试验因入组缓慢在54例时提前终止。
  • 虽未针对比较进行功效计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare in a phase III trial the efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine (GA) with that of carboplatin plus gemcitabine (GCb) as a first-line treatment for patients with cisplatin-ineligible metastatic urothelial cancer (mUC). PATIENTS AND METHODS: Treatment-naive, cisplatin-ineligible patients with mUC were assigned randomly to either the GA (both nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on Days 1 and 8, every 21 days) or GCb group (carboplatin area under the free carboplatin plasma concentration versus time curve of 4.5 on Day 1, gemcitabine 1000 mg/m2 on Days 1 and 8, every 21 days). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), safety, and patient-reported outcomes (PROs). RESULTS: The trial was terminated early because of slow accrual after 54 patients were enrolled: 26 in in the GA group and 28 in the GCb groups. The median PFS was 6.7 vs 5.9 months for the GA and GCb groups, respectively (P = 0.248). The median OS time was 12.1 vs 10.7 months for the GA and GCb groups, respectively (P = 0.837). The ORR and DCR were 40% vs 46.4% (P = 0.637) and 72% vs 68% (P = 0.188) in the GA and GCb groups, respectively. Patients treated with GA showed significantly lower incidence of Grade 3-4 thrombocytopenia and does reduction and delay. Although peripheral sensory neuropathy was higher in the GA arm, no Grade 3 neuropathy occurred. There was no difference in the PROs between the two groups. CONCLUSION: While not powered for comparison, first-line GA showed similar efficacy and better tolerability and might be considered a rational alternative to GCb.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. An X, Xue C, Chen M, et al. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma. BJU Int. 2024. PMID: 38009394. doi:10.1111/bju.16241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。